Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regenerative Medicine Group Says Cures Act Will Help Industry

Executive Summary

The 21st Century Cures Act will require US FDA to create standards and an expedited approval process for regenerative medicine products. Trade group ARM supports the efforts.

You may also be interested in...



Crackdown On Bad Regenerative Medicine Actors By US FDA Could Benefit Honest Developers

The agency plans to offer a series of guidance documents on regenerative product development as enforcement against "unscrupulous actors" continues.

21st Century Cures: Device Provisions

Dozens of reforms impacting the medtech sector were signed into law Dec. 13 as part of the 21st Century Cures Act. Here's a breakdown of the provisions most important to device- and diagnostic-makers.

Abbott Claims DexCom CGM Suits Renege On Tech-Sharing Agreement

Abbott says DexCom’s patent suits involve technology that was already the subject of a settlement, and raise venue questions.

Topics

UsernamePublicRestriction

Register

MT104181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel